S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis
Related Posts
EdgeQ Closes $75M Series-B Investment and Ramps to Customers’ Demand for Its Award-Winning 5G+AI Base Station-on-a-Chip for 5G Networks
- 02 05 2023
- |
Proxtera announces successful first close, of Series Seed round of funding with Ant Group, CerraCap Ventures, and EDBI
- 30 03 2023
- |
